Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Epidarex Capital

Investor type Micro VC

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 37
Average round size
info
The average size of a deal this fund participated in
$13M
Portfolio companies 24
Rounds per year 3.08
Lead investments 14
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.35
Exits 3
Key employees 4
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Therapeutics
  • Health Care
  • Medical
  • Health Diagnostics
Summary

Epidarex Capital appeared to be the VC, which was created in 2010. The company was established in North America in United States. The main office of represented VC is situated in the Bethesda.

The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Epidarex Capital, startups are often financed by Mercury Fund, Kei Aar, Imperial Innovations. The meaningful sponsors for the fund in investment in the same round are Scottish Investment Bank, venBio Partners, Imperial Innovations. In the next rounds fund is usually obtained by [email protected], Innovate UK, Imperial Innovations.

We also calculated 4 valuable employees in our database.

Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Clyde Biosciences, Sirakoss, Mironid. For fund there is no match between the location of its establishment and the land of its numerous investments - United Kingdom. Among the most successful fund investment fields, there are Medical, Health Diagnostics. The fund has exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager.

The high activity for fund was in 2015. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year. The higher amount of exits for fund were in 2017. The real fund results show that this VC is 40 percentage points more often commits exit comparing to other companies. Comparing to the other companies, this Epidarex Capital performs on 19 percentage points less the average number of lead investments. The usual things for fund are deals in the range of 10 - 50 millions dollars.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Epidarex Capital:
Typical Co-investors
Epidarex Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Epidarex Capital:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Aereco -
Baohui Equity Investment China, Fujian, Xiamen
C&I Capital Beijing, Beijing, China
CKGSB Alumni Chuangchuang Fund Beijing, Beijing, China
Convivialite Ventures California, San Francisco, United States
Emkan Capital Ar Riyad, Riyadh, Saudi Arabia
Firminvest -
Goal Ventures -
Huaxin Capital China, Guangdong, Shenzhen
Indicator Ventures New York, New York, United States
Lowe's Ventures Mooresville, North Carolina, United States
M6 Ventures California, La Jolla, United States
New York Times Digital New York, New York, United States
Penn Venture Partners Harrisburg, Pennsylvania, United States
ROOBO Beijing, Beijing, China
Silver Chalice Ventures Chicago, Illinois, United States
SMASHD Labs California, Culver City, United States
The CDMN Soft-Landing Program Canada, Kitchener, Ontario
The Kraft Group Boxborough, Massachusetts, United States
Zhuhai Ailai Investment China, Guangdong, Zhuhai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Transine Therapeutics

Biotechnology
Life Science
$6M31 May 2022 Cambridge, England, United Kingdom

Kynos Therapeutics

Biotechnology
Health Care
Medical
Therapeutics
$8M07 Apr 2022 -

IGEM Therapeutics

Biotechnology
Genetics
Therapeutics
02 Mar 2022 London, England, United Kingdom

Dunad Therapeutics

Biotechnology
Pharmaceutical
$24M02 Nov 2021 London, England, United Kingdom

Leucid Bio

Biotechnology
$15M21 Oct 2021 London, England, United Kingdom

Macomics

Biotechnology
Therapeutics
$5M29 Jul 2021 City of Edinburgh, Scotland, United Kingdom

RapidPulse

Health Care
Medical Device
$15M23 Jun 2021 Miami, Florida, United States

Lunac Therapeutics

Biotechnology
Therapeutics
$6M17 May 2021 Leeds, England, United Kingdom

Dunad Therapeutics

Biotechnology
Pharmaceutical
23 Mar 2021 London, England, United Kingdom
News
Macomics, the Macrophage-based Drug Discovery company, secures £4.24m expansion financing, and appoints CEO, CSO and VP Immunology

– Macomics Ltd has closed a follow-on financing of £4.24m from its 2020 Seed round, bringing the total amount raised to £7.44m.
– The additional investment brings in new investor Caribou Property Limited alongside existing investors Epidarex Capital, who led the round, and Scottish Enterprise.
– It will be used to accelerate the company’s growth, including expansion of the team.
– Macomics is developing precision medicines to modulate macrophages for the treatment of cancer.
– The company was co-founded in 2019 by Prof Jeffrey Pollard and Dr Luca Cassetta, University of Edinburgh, internationally recognised leaders in macrophage biology.
– It is progressing a diversified portfolio of therapies targeting disease specific tumour associated macrophages (‘TAMs’) towards the clinic.

Theolytics Expands Series A Funding Round

– Theolytics, an Oxford, UK-based developer of a library of potential adenovirus product candidates and breakthrough bioselection systems, raised new funding from M Ventures.
– Funding was joined by Epidarex Capital and Taiho Ventures in an extension to the Series A financing.
– The expanded Series A funding will support the progress of internal programmes in ovarian cancer, and a second cancer indication in addition to further advancing the company’s technology platforms.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Epidarex Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: